Want to see XAIR full AI Analyst Report?
XAIR Stock Chart & Stats
$5.36
$0.21(3.97%)
At close: 4:00 PM EDT
$5.36
$0.21(3.97%)
Day’s Range― - ―
52-Week Range$5.10 - $95.60
Previous Close$5.37
Volume15.95K
Average Volume (3M)18.32K
Market Cap
$3.97M
Enterprise Value$15.38
Total Cash (Recent Filing)$11.64M
Total Debt (Recent Filing)$23.38M
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-88.00
Shares Outstanding720,531
10 Day Avg. Volume28,112
30 Day Avg. Volume18,318
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.93
Price to Sales (P/S)0.75
P/FCF Ratio-0.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.78
Revenue Forecast (FY)$12.70M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained double-digit top-line growth demonstrates meaningful commercial traction for the LungFit platform and growing adoption across markets. An expanding installed base supports recurring consumables revenue and provides a foundation for scale-driven margin improvement and longer-term revenue visibility.
Gross Profit & Operating ImprovementA swing to positive gross profit and sizable operating improvement indicate improving unit economics and effective cost control. If sustained, these trends support a path to operating leverage as revenue rises, reducing the reliance on continual dilutive financing to reach profitability over the medium term.
Commercial Reach & High RetentionHigh retention and major GPO agreements materially expand hospital access and create predictable replacement and consumable demand. Broad international clearances diversify market exposure, supporting recurring revenue streams and strengthening the company’s commercial moat versus early-stage competitors.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the business cannot self-fund growth today and remains dependent on external capital. This ongoing burn constrains strategic investments, increases financing risk, and can force dilutive equity raises or restrict commercial scale-up if funding conditions deteriorate.
Limited Liquidity Vs. DebtA modest cash balance versus sizable long-term debt and a high annualized cash burn narrows runway and reduces financial flexibility. Near-term capital needs could require dilutive financings or covenant negotiations, which would impact the firm’s ability to execute a Gen 2 launch and sustain commercial expansion.
Regulatory Dependence For GrowthFuture revenue and materially larger TAM hinge on timely FDA approval of the Gen 2 LungFit system. Regulatory outcome and timing are inherently uncertain and can delay or reduce projected market expansion, complicating revenue forecasts, commercial planning, and capital requirements over the medium term.
Beyond Air News
XAIR FAQ
What was Beyond Air Inc’s price range in the past 12 months?
Beyond Air Inc lowest stock price was $5.10 and its highest was $95.60 in the past 12 months.
What is Beyond Air Inc’s market cap?
Beyond Air Inc’s market cap is $3.97M.
When is Beyond Air Inc’s upcoming earnings report date?
Beyond Air Inc’s upcoming earnings report date is Aug 11, 2026 which is in 10 days.
How were Beyond Air Inc’s earnings last quarter?
Beyond Air Inc released its earnings results on Jun 26, 2026. The company reported -$15.4 earnings per share for the quarter, missing the consensus estimate of -$11.333 by -$4.067.
Is Beyond Air Inc overvalued?
According to Wall Street analysts Beyond Air Inc’s price is currently Overvalued.
Does Beyond Air Inc pay dividends?
Beyond Air Inc does not currently pay dividends.
What is Beyond Air Inc’s EPS estimate?
Beyond Air Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyond Air Inc have?
Beyond Air Inc has 720,531 shares outstanding.
What happened to Beyond Air Inc’s price movement after its last earnings report?
Beyond Air Inc reported an EPS of -$15.4 in its last earnings report, missing expectations of -$11.333. Following the earnings report the stock price went up 3.708%.
Which hedge fund is a major shareholder of Beyond Air Inc?
Currently, no hedge funds are holding shares in XAIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyond Air Inc
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
XAIR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear commercial progress: strong revenue growth (>107% to $7.7M), improved gross profit and operating results, high customer retention (~90%), expanded GPO relationships and global clearances, and a compelling product roadmap with Gen 2 that could materially expand the addressable market. Offsetting these positives are remaining sizable net losses ($33.2M), limited cash on hand ($17.3M) versus $21.6M of long-term debt, increased other expenses, a Nasdaq compliance-driven reverse split, and dependence on uncertain FDA timing for Gen 2 approval (which underpins 2027 guidance). Overall, momentum and execution improvements are evident, but material execution and financing/regulatory risks remain.View all XAIR earnings summariesXAIR Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
62.97% Insiders
1.56% Mutual Funds
― Other Institutional Investors
35.04% Public Companies and
Individual Investors